Mahmoudi E, Lin P, Ratakonda S, Khan A, Kamdar N, Peterson MD. Preventative services use and risk reduction for potentially preventative hospitalizations among people with traumatic spinal cord injury. Arch Phys Med Rehabil. 2022 Jul;103(7):1255-62. doi: 10.1016/j.apmr.2021.12.004
Chung AH, Leisner TM, Dardis GJ, Bivins MM, Keller AL, Parise LV. CIB1 depletion with docetaxel or TRAIL enhances triple-negative breast cancer cell death. Cancer Cell Int. 2019 Feb 4;19(26). doi: 10.1186/s12935-019-0740-2
Ward MA, Fang G, Richards KL, Walko CM, Earnshaw SR, Happe LE, Blalock S. Treatment interruption and regimen change in first-generation vs. second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia. JHEOR. 2015 Apr;2(2):181-91.
Davis KL, Gutierrez B, Zyczynski T, Kaye JA. Real-world treatment patterns in men with castration-resistant prostate cancer receiving docetaxel. JHEOR. 2015 Jan 6;2(2):119-30. doi: 10.36469/9894
Brodtkorb T, Henriksson M, Johannesen-Munk K, Thidell F. Cost-effectiveness of C-leg compared with non-microprocessor-controlled knees: a modeling approach. Arch Phys Med Rehabil. 2008;89(1):24-30.